Short answer: Ovarian platelet-rich plasma, often called ovarian PRP, is an experimental fertility add-on in which a concentrated preparation made from the patient's own blood is injected into ovarian tissue. It is sometimes promoted for low ovarian reserve, poor ovarian response, or age-related fertility decline. Current evidence is not strong enough to show that ovarian PRP reliably improves egg quality, pregnancy, or live birth, and it should not be presented as a proven rejuvenation treatment.
Patients considering PRP should receive balanced counseling about uncertainty, alternatives, cost, procedure risks, and the possibility that treatment may not change the IVF plan. IVF Turkey does not treat an increase in AMH or a change in follicle count as proof that a patient will have a higher chance of live birth. The decision must remain case-specific and should not delay standard fertility care without a clear medical reason.
What is ovarian PRP?
PRP is prepared by drawing blood and processing it to concentrate platelets and growth-related proteins. In ovarian PRP procedures, the preparation is introduced into the ovaries, usually with an ultrasound-guided technique. Protocols vary between providers, including how blood is processed, how much material is injected, when the procedure occurs, and how outcomes are measured.
This lack of standardization makes studies difficult to compare. A result from one protocol cannot automatically be applied to another clinic or patient group. Ovarian PRP should therefore be described as experimental rather than routine IVF care.
What does the evidence show?
Some small or uncontrolled studies have reported changes in AMH, antral follicle count, menstrual patterns, oocyte numbers, or pregnancy outcomes after PRP. These observations can generate research questions, but they do not prove that PRP caused the change. Ovarian reserve markers can vary, patients may receive other treatment at the same time, and studies may lack suitable control groups.
The most important outcomes are not isolated hormone changes. Patients need to know whether an intervention improves the chance of obtaining a usable embryo, achieving an ongoing pregnancy, and ultimately having a live birth without unacceptable risk. Larger randomized studies with standardized protocols and longer follow-up are needed before ovarian PRP can be recommended as established treatment.
Who is most often offered PRP?
PRP is commonly marketed to patients with low AMH, diminished ovarian reserve, previous poor response to stimulation, repeated unsuccessful IVF cycles, or older reproductive age. These groups already have variable outcomes, so an individual improvement after treatment cannot establish effectiveness. Age, antral follicle count, previous response, sperm findings, embryo development, and uterine factors still need full review.
Patients with low ovarian reserve should first understand what AMH can and cannot predict. The initial fertility testing guide explains how AMH and ultrasound are interpreted. A review of ovarian stimulation protocols may identify standard adjustments that have clearer clinical rationale than an experimental add-on.
Risks and practical considerations
Because PRP is made from a patient's own blood, allergic reaction may be less likely than with a donor-derived product, but autologous does not mean risk-free. Ovarian injection can involve pain, bleeding, infection, injury to nearby structures, anesthesia or sedation risks, and delay to planned IVF treatment. Clinics should explain sterile processing, operator experience, emergency arrangements, and what follow-up is included.
Financial risk also matters. Experimental add-ons may be paid privately and may require extra appointments, medication changes, or travel. Patients should request a written price and ask whether the procedure changes the IVF schedule. A refund or guaranteed-success claim should not substitute for evidence.
Questions to ask before deciding
- Is ovarian PRP classified as experimental by this clinic?
- What patient group and outcome evidence supports offering it to me?
- Is the goal a hormone change, more eggs, usable embryos, or live birth?
- What are the procedure, anesthesia, infection, and bleeding risks?
- What standard treatment alternatives should be considered first?
- Will PRP delay IVF, and what happens if there is no response?
What should happen before an add-on?
A fertility specialist should review recent AMH, antral follicle count, age, previous stimulation records, mature egg number, fertilization, embryo development, semen analysis, uterine findings, medications, and medical risks. If previous cycles failed, the multiple IVF failures guide can help structure that review. The aim is to identify whether a standard change is more likely to affect care.
Patients should also be told when proceeding directly with IVF, seeking a second opinion, or reconsidering the treatment goal may be more appropriate than waiting for an add-on. No intervention should be described as creating new eggs or reversing reproductive age.
FAQ
Can ovarian PRP increase AMH?
Some studies report changes, but AMH variation alone does not prove improved egg quality or live birth. The clinical meaning remains uncertain.
Is ovarian PRP proven to improve IVF success?
No. Evidence is still insufficient to treat it as established care or promise improved pregnancy or live-birth outcomes.
Is PRP safe because it uses my own blood?
Using autologous blood does not remove procedural risks such as pain, bleeding, infection, sedation complications, or treatment delay.
Next step
If you are considering ovarian PRP, gather your test results and complete previous IVF records before deciding. You can contact IVF Turkey for a doctor-reviewed discussion of standard options, uncertainties, and whether an experimental add-on should be considered at all.